Prolocor is a Philadelphia, PA-based healthcare startup developing a precision diagnostic test that quantifies FcγRIIa (the pFCG test) to predict thrombosis risk. The company's prognostic tool aims to guide treatment decisions by matching therapy intensity to a patient’s risk of events. Led by CEO Dr. Peter DiBattiste and CSO Dr. David Schneider, Prolocor is advancing its clinical program. The company raised $1.7M in bridge funding to support its near-term plans. Prolocor intends to use the funds for its ongoing clinical program and to commercialize the test in 2024. Prolocor is building an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets to assess thrombotic risk. The core product aims to help clinicians match intensity of antithrombotic therapy to individual patient risk, balancing thrombosis and bleeding. The company emphasizes expertise in thrombosis and cardiovascular disease among its founding team. With new funding, Prolocor plans to establish a CLIA-certified laboratory and complete analytical validation of platelet FcγRIIa as a precision tool. Prolocor is also conducting a prospective, observational multicenter non-interventional cohort study of 800 patients who have experienced heart attacks. The company intends to use the funds to move the technology from lab validation toward clinical application.

Total raised

$9M

Funding rounds

3

Latest round

Convertible Note

Latest activity

Mar 2024